Phase I clinical trial of HC‐1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single‐dose proportionality and effects of food

BACKGROUND: Preclinical studies showed that HC‐1119, a deuterated version of enzalutamide, could competitively inhibit androgen binding to androgen receptor by blocking the transmission of androgen receptor signaling pathway as enzalutamide, inducing apoptosis of prostate cancer cells and reducing t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Haiping, Xu, Weidong, Ni, Jin, Zhao, Naping, Tang, Shouyan, Li, Song, Cai, Tingting, Xiu, Jianping, Kang, Xin, Gao, Shen, Zhang, Li, Zhou, Tie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298787/
https://www.ncbi.nlm.nih.gov/pubmed/34807458
http://dx.doi.org/10.1002/pros.24271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298787/
https://www.ncbi.nlm.nih.gov/pubmed/34807458
http://dx.doi.org/10.1002/pros.24271

Ejemplares similares